ylliX - Online Advertising Network
Press Release

Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease

Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease

<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>

Second Dupixent ® (dupilumab) Phase 3 e osinophilic e sophagitis t rial to d emonstrate s ignificant d isease i mprovements, u nderscoring r ole of t ype 2 i nflammation in t his c omplex d isease

...read full article on GlobeNewsWire

ylliX - Online Advertising Network